​A cardiovascular biobank – a systematically organized storage facility for human blood and tissue specimens from patients with cardiovascular diseases – is a key element to help us gain a better understanding of how these diseases develop and how we may treat them.

We can't achieve the transformative benefits of both molecular and personalized medicine without analyzing the genetic and proteomic structures of human tissue specimens and completing biochemical, physiological and clinical investigations using human tissue specimens. This research will enable us to develop the next generation of diagnostic and therapeutic approaches.

The Peter Munk Cardiac Centre Cardiovascular Biobank aims to promote cardiovascular health through the development of:

  • A molecular and genetic-level understanding of the progression of cardiovascular diseases
  • Biomarkers for diagnostic and prognostic purposes
  • Identification of novel therapeutic targets for treatment

Our Vision is to foster translational research that focuses on the prevention, diagnosis and treatment of cardiovascular illnesses and the promotion of cardiovascular health.

Our Mission is to establish and maintain a standardized approach to the collection, management, distribution and use of human specimens for research purposes.

Our Objective is to provide our researchers with better access to blood and tissue specimens from patients suffering from cardiovascular diseases, promoting appropriate standards of quality and security.

A team of pathologists, researchers and clinicians oversees the biobank.


How biobanks are transforming health care

The drug Herceptin is an excellent example of the impact of biobanks on health care. By screening banked tissue samples, researchers discovered that Herceptin, an antibody targeting a receptor on the surface of breast cancer cells, is an effective treatment for HER-2 positive types of breast cancer, increasing survival rates for many women with breast cancer.